Advances in targeting 'undruggable' transcription factors with small molecules
- PMID: 34006959
- DOI: 10.1038/s41573-021-00199-0
Advances in targeting 'undruggable' transcription factors with small molecules
Abstract
Transcription factors (TFs) represent key biological players in diseases including cancer, autoimmunity, diabetes and cardiovascular disease. However, outside nuclear receptors, TFs have traditionally been considered 'undruggable' by small-molecule ligands due to significant structural disorder and lack of defined small-molecule binding pockets. Renewed interest in the field has been ignited by significant progress in chemical biology approaches to ligand discovery and optimization, especially the advent of targeted protein degradation approaches, along with increasing appreciation of the critical role a limited number of collaborators play in the regulation of key TF effector genes. Here, we review current understanding of TF-mediated gene regulation, discuss successful targeting strategies and highlight ongoing challenges and emerging approaches to address them.
© 2021. Springer Nature Limited.
Similar articles
-
Current strategies and progress for targeting the "undruggable" transcription factors.Acta Pharmacol Sin. 2022 Oct;43(10):2474-2481. doi: 10.1038/s41401-021-00852-9. Epub 2022 Feb 7. Acta Pharmacol Sin. 2022. PMID: 35132191 Free PMC article. Review.
-
Frontiers in PROTACs.Drug Discov Today. 2021 Oct;26(10):2377-2383. doi: 10.1016/j.drudis.2021.04.010. Epub 2021 Apr 17. Drug Discov Today. 2021. PMID: 33872800 Review.
-
Reimagining Druggability Using Chemoproteomic Platforms.Acc Chem Res. 2021 Apr 6;54(7):1801-1813. doi: 10.1021/acs.accounts.1c00065. Epub 2021 Mar 18. Acc Chem Res. 2021. PMID: 33733731 Review.
-
Drug-Induced Expression-Based Computational Repurposing of Small Molecules Affecting Transcription Factor Activity.Methods Mol Biol. 2019;1903:179-184. doi: 10.1007/978-1-4939-8955-3_10. Methods Mol Biol. 2019. PMID: 30547442
-
Protein degradation technology: a strategic paradigm shift in drug discovery.J Hematol Oncol. 2021 Sep 6;14(1):138. doi: 10.1186/s13045-021-01146-7. J Hematol Oncol. 2021. PMID: 34488823 Free PMC article. Review.
Cited by
-
CRISPR perfect adaptation for robust control of cellular immune and apoptotic responses.Nucleic Acids Res. 2024 Sep 9;52(16):10005-10016. doi: 10.1093/nar/gkae665. Nucleic Acids Res. 2024. PMID: 39087566 Free PMC article.
-
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.Signal Transduct Target Ther. 2023 Sep 6;8(1):335. doi: 10.1038/s41392-023-01589-z. Signal Transduct Target Ther. 2023. PMID: 37669923 Free PMC article. Review.
-
Affinity chromatography reveals direct binding of the GATA4-NKX2-5 interaction inhibitor (3i-1000) with GATA4.Sci Rep. 2024 Apr 18;14(1):8938. doi: 10.1038/s41598-024-59418-4. Sci Rep. 2024. PMID: 38637629 Free PMC article.
-
The role of transcription factors in the crosstalk between cancer-associated fibroblasts and tumor cells.J Adv Res. 2025 Jan;67:121-132. doi: 10.1016/j.jare.2024.01.033. Epub 2024 Feb 2. J Adv Res. 2025. PMID: 38309692 Free PMC article. Review.
-
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.Signal Transduct Target Ther. 2023 Nov 13;8(1):427. doi: 10.1038/s41392-023-01651-w. Signal Transduct Target Ther. 2023. PMID: 37953273 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous